Big pharma and healthcare providers join forces to promote wellbeing
Wednesday, February 5, 2014
When the G8 met in London in December 2013 to consider the global challenge of dementia, something new and different happened.
Rather than being on the outside, the pharmaceuticals and biotech industries were included in the discussion of how to meet the challenge of caring for a projected 100 million people with Alzheimer’s disease by 2050.
“It brought together academics, researchers, regulators, scientists and pharmaceuticals companies in a way that was very new and very different,” says Karen Manson, senior director for global citizenship and sustainability at Janssen, a research-based pharmaceuticals company.
- Health Care